LOGIN  |  REGISTER
Assertio

Waters Sets New Standards for High Resolution Performance and Speed with Xevo MRT Mass Spectrometer

June 03, 2024 | Last Trade: US$368.16 7.53 2.09

News Summary:

  • Waters Xevo™ MRT Mass Spectrometer employs next-generation multi-reflecting time-of-flight technology to deliver class-leading combination of high resolution and speed without compromising analytical performance.i
  • Delivers up to 6x resolution at maximum speed and up to 2x mass accuracy of competitive systems,ii enabling scientists to process more samples in less time for large-cohort biomedical research and epidemiology-type studies.
  • Complete workflows available for metabolomic, lipidomic, and metabolite identification enables customer flexibility and convenience using Waters™ software, columns, and instruments for high throughput separations, and universal data-sharing with third-party software applications.

ANAHEIM, Calif., and MILFORD, Mass., June 3, 2024 /PRNewswire/ -- 72nd ASMS Conference on Mass Spectrometry and Allied Topics – Waters Corporation (NYSE: WAT) today unveiled the Xevo™ MRT, its highest-performing benchtop mass spectrometer (MS), setting new standards for delivering high resolution and speed, critical for large population and epidemiology-type studies. It builds on the innovative technology pioneered by the Waters SELECT SERIES™ MRT MS. The new Xevo MRT MS combines the raw power and resolution speed of multi-reflecting time-of-flight (MRT) and hybrid quadrupole time-of-flight (QTof) technologies within a flexible benchtop platform.

"Understanding complex diseases requires analysis of thousands of samples from large human cohorts to provide statistically valid studies. This puts increased pressure on drug discovery scientists to deliver high-quality data in shorter run times," said Dr. Udit Batra, CEO and President of Waters Corporation. "The Xevo MRT mass spectrometer is a next generation QTof built from the ground up to address this unmet need, delivering high resolution and speed without compromising analytical performance. Its multi-reflecting time-of-flight design enables simultaneous high sensitivity, high resolution, and speed in a small footprint, accelerating time-to-results and ensuring high-quality experimental outcomes."

The Xevo MRT system delivers a class-leadingiii 100,000 full width half maximum (FWHM) resolution at 100 Hz MS/MS scan speed and <500 parts per billion (ppb) mass accuracy. This enables deeper probing of biologically relevant concentrations with high levels of mass accuracy, independent of acquisition rate.

"A range of mass spec approaches are available for metabolomic, lipidomic, and metabolite identification studies, yet all require compromises to be made - either in data quality or analytical efficiency," said Professor Perdita Barran, Chair of Mass Spectroscopy in the University of Manchester (UK) Department of Chemistry and Director of the Michael Barber Centre for Collaborative Mass Spectrometry at the Manchester Institute of Biotechnology. "The Xevo MRT MS is impressive technology capable of higher sample throughput combined with extremely high precision, which can significantly advance target validation and phenotyping studies. The increase in scan speed and data quality are critical as it can allow us to run more samples in less time without compromising confidence in our data and we are very excited by how this is allowing us to accelerate the development of a diagnostic test for Parkinson's Disease."

The innovative multi-reflecting time-of-flight design of the Xevo MRT MS offers scientists the power to work at maximum resolution with high sensitivity and fast data acquisition rates. This helps ensure confident identification of analytes across a range of samples and complex matrices and generate comprehensive and highly accurate mass data for scientific interpretation.

Waters offers complete workflows for metabolomic, lipidomic, and metabolite identification for the Xevo MRT MS, alongside Waters high throughput ACQUITY™ UPLC™ Systems and UPLC Column chemistries and waters_connect™ Software for data acquisition, processing, and reporting. The system supports universal data-sharing via mzML file formats with third-party informatics software, including popular applications from Mass Analytica™ such as its MARS, Lipostar2, and MassMetaSite software offerings.

The Waters Xevo MRT MS is orderable today for shipment in the second half of 2024.

Additional Resources

About Waters Corporation (www.waters.com)

Waters Corporation (NYSE: WAT), a global leader in analytical instruments and software, has pioneered chromatography, mass spectrometry, and thermal analysis innovations serving the life, materials, food, and environmental sciences for more than 65 years. With approximately 7,700 employees worldwide, Waters operates directly in 35 countries, including 15 manufacturing facilities, and with products available in more than 100 countries.

Waters, Xevo, SELECT SERIES, ACQUITY, UPLC, and waters_connect are trademarks of Waters Technologies Corporation. Mass Analytica is a trademark of Mass Spec Analytica, S.L.

Contact:
Janice Foley
Senior Public Relations Manager, Corporate Communications
Waters Corporation
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1.617.823.5555

i Estimates based on Xevo MRT MS performance comparison to competitor instruments @100Hz @m/z 956 = 100K FWHM and <500ppb mass accuracy.
ii Xevo MRT MS Resolution of 100K FWHM @ m/z 956 is up to 1.5x to 6x competitor instruments @100Hz; Xevo MRT Mass Accuracy of <500ppb is 2x competitor systems @ 1ppm.
iii Xevo MRT MS Resolution of 100K FWHM @ m/z 956 is up to 1.5x to 6x competitor instruments @100Hz; Xevo MRT Mass Accuracy of <500ppb is 2x competitor systems @ 1ppm.

Waters Xevo MRT multi-reflecting hybrid QTof mass spectrometer delivers 100K FWHM resolution at 100 Hz with sub-ppm mass accuracy for confident identification and greater laboratory productivity.

Recursion

Stock Quote

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB